Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-004301
Filing Date
2025-02-14
Accepted
2025-02-14 18:42:37
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10844
2 JOINT FILING AGREEMENT ex-99-02142025_110237.htm EX-99.1 4478
  Complete submission text file 0001415889-25-004301.txt   17156
Mailing Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Business Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, L.P. (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Subject) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92757 | Film No.: 25631804
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)